Annuncio • Apr 01

ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile

ORIC Pharmaceuticals, Inc. announced a rinzimetostat (ORIC-944) program update and potential best-in-disease efficacy and safety data from the Phase 1b trial of once daily rinzimetostat in combination with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with abiraterone acetate (abiraterone). Rinzimetostat 400 mg once daily was selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone mCRPC, with initiation expected in the first half of 2026. At a median follow-up of approximately 5 months, landmark 5-month rPFS of 84% is consistent with competitor PRC2 inhibitor and substantially better than standard of care therapies in mCRPC. Highly differentiated, potential best-in-disease safety profile, with significantly lower frequency and severity of adverse events, nearly all Grade 1 or 2, and far fewer treatment modifications than competitor regimens. Patients were previously treated with a median of two prior lines of therapy, including abiraterone, up to one prior line of chemotherapy, and a variety of other approved and investigational treatment regimens. 18 patients were treated with 400 mg of rinzimetostat once daily and 15 patients were treated with 600 mg of rinzimetostat once daily, both in combination with the standard dose of darolutamide at 600 mg twice daily. At the 400 mg dose, rinzimetostat in combination with darolutamide continues to be well tolerated and demonstrates a safety profile supportive of long-term administration and sustained patient adherence. As of the January 16, 2026 data cutoff, the vast majority of treatment-related adverse events (TRAEs) were Grade 1 in severity and consistent with PRC2 and AR inhibition. The most common TRAEs were fatigue (39%; 17% Grade 1 and 22% Grade 2), diarrhea (22%; 17% Grade 1 and 6% Grade 2) and nausea (22%; all Grade 1). A single Grade 3 TRAE was observed, and no Grade 4 or 5 AEs were attributed to rinzimetostat or darolutamide. Dose modifications were rare (one interruption and one discontinuation), with no dose reductions required. The 600 mg dose of rinzimetostat in combination with darolutamide was associated with a modestly higher rate of adverse events and dose modifications. In a broader dataset of post-ARPI (androgen receptor pathway inhibitor) patients (n=72, inclusive of the post-abiraterone patients), the safety and tolerability profile was consistent with the post-abiraterone cohort. To support the selection of the recommended Phase 3 dose in accordance with the FDA's Project Optimus initiative, the company conducted a comprehensive exposure-response (E-R) analysis in over 100 patients across both the single-agent and combination data evaluating the relationship between rinzimetostat drug exposure versus efficacy and safety outcomes. The analysis demonstrated that 400 mg and 600 mg once daily provided comparable efficacy. In contrast, the E-R analysis identified statistically significant relationships between higher drug exposure and toxicities as well as increased rates of treatment modifications, clearly favoring the 400 mg dose on the basis of safety. Based on these findings 400 mg once daily in combination with darolutamide has been selected as the RP3D for rinzimetostat. As of March 6, 2026, radiographic progression-free survival (rPFS) was assessed in 18 efficacy-evaluable patients. PSA responses were assessed in a subset of 15 patients with at least one post-baseline assessment as of the January 16, 2026 clinical cutoff. ctDNA molecular response was evaluated in 14 patients with detectable ctDNA at baseline. Early efficacy data, including landmark rPFS rates, PSA reductions and ctDNA responses, are suggestive of meaningful and durable clinical benefit for rinzimetostat in combination with darolutamide compared to competitor data and historical outcomes with approved therapies. Rinzimetostat 400 mg once daily in combination with darolutamide demonstrated compelling efficacy across multiple endpoints: With a median follow up of 4.9 months, landmark rPFS rates of 93%, 84%, and 84% at 3, 4, and 5 months, respectively, are consistent with the competitor PRC2 inhibitor currently in Phase 3 in post-abiraterone mCRPC patients and superior to available standard-of-care therapies, including Xtandi, Jevtana, Taxotere, and Pluvicto. For reference, the 5-month landmark rPFS for these approved therapies ranges from approximately 60% to 75%. 47% of patients (7/15) achieved a PSA50 response, with 33% (5/15) confirmed. Impressive ctDNA reductions observed across a range of AR mutations, with 71% of patients (10/14) achieving >50% ctDNA reduction. The company expects to initiate the Himalayas-1 global Phase 3 registrational trial in mCRPC patients previously treated with abiraterone in the first half of 2026. This proposed trial will enroll approximately 600 patients from over 250 sites in over 20 countries, randomized 1:1 to receive the RP3D of 400 mg QD rinzimetostat in combination with darolutamide versus physician’s choice of an AR inhibitor or chemotherapy. The primary endpoint is rPFS, the key secondary endpoint is overall survival, and additional secondary endpoints include PSA response rate, objective response rate and patient reported outcomes. In the US, the annual incidence of mCRPC patients previously treated with abiraterone is approximately 17,000, with an estimated addressable market of greater than $3,500 million and total global addressable market of $7,000 million. This market lacks oral, well-tolerated therapies with meaningful efficacy. Rinzimetostat 400 mg QD plus darolutamide is currently being evaluated in a food effect cohort. Thus far, there does not appear to be a significant food effect, consistent with previous single agent studies. Furthermore, as of March 6, 2026, early efficacy and safety are consistent with fasted results, with two confirmed PSA50 responses and one confirmed PSA90 response in the first five patients dosed, and all TRAEs reported being Grade 1 with a single Grade 2 TRAE. The company is also evaluating additional prostate cancer populations for future potential Phase 3 trials in mCRPC and mCSPC. Early data from rinzimetostat in 19 patients with mCRPC previously treated with AR inhibitors demonstrated compelling landmark rPFS rates of 93%, 85%, and 85% at 3, 4, and 5 months, respectively, with a median follow-up of 4.8 months. Rinzimetostat is being evaluated in a Phase 1b dose optimization trial in combination with ERLEADA (apalutamide), Johnson & Johnson’s AR inhibitor, and NUBEQA (darolutamide), Bayer’s AR inhibitor, in patients with mCRPC. Patients are eligible if they have received prior treatment with an ARPI and up to one prior chemotherapy. The primary objective of the trial is to determine the RP3D, and additional objectives include safety, tolerability, pharmacokinetics, and preliminary clinical activity.

Biotechs crescita degli utili	23.4%
Tasso di crescita dei ricavi	56.6%
Rendimento futuro del capitale proprio	-46.25%
Copertura analitica	Good
Ultimo aggiornamento	27 May 2026

Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2028	8	-231	N/A	-200	8
12/31/2027	N/A	-180	-130	-152	10
12/31/2026	N/A	-154	-107	-117	12
3/31/2026	N/A	-135	-111	-111	N/A
12/31/2025	N/A	-129	-112	-111	N/A
9/30/2025	N/A	-135	-117	-117	N/A
6/30/2025	N/A	-137	-121	-120	N/A
3/31/2025	N/A	-133	-116	-115	N/A
12/31/2024	N/A	-128	-114	-113	N/A
9/30/2024	N/A	-120	-110	-109	N/A
6/30/2024	N/A	-111	-100	-100	N/A
3/31/2024	N/A	-102	-96	-95	N/A
12/31/2023	N/A	-101	-87	-86	N/A
9/30/2023	N/A	-93	-78	-77	N/A
6/30/2023	N/A	-93	-78	-76	N/A
3/31/2023	N/A	-90	-75	-73	N/A
12/31/2022	N/A	-89	-77	-75	N/A
9/30/2022	N/A	-91	-78	-76	N/A
6/30/2022	N/A	-85	-71	-69	N/A
3/31/2022	N/A	-85	-69	-67	N/A
12/31/2021	N/A	-79	-60	-60	N/A
9/30/2021	N/A	-84	-62	-61	N/A
6/30/2021	N/A	-91	-59	-59	N/A
3/31/2021	N/A	-81	-53	-52	N/A
12/31/2020	N/A	-74	-46	-45	N/A
9/30/2020	N/A	-54	-35	-35	N/A
6/30/2020	N/A	-35	-31	-30	N/A
3/31/2020	N/A	-30	-27	-26	N/A
12/31/2019	N/A	-27	N/A	-24	N/A
12/31/2018	N/A	-21	N/A	-21	N/A

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/27 10:56
Prezzo dell'azione a fine giornata	2026/05/27 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

Analista	Istituzione
Colleen Kusy	Baird
Prakhar Agrawal	Cantor Fitzgerald & Co.
Yigal Nochomovitz	Citigroup Inc

ORIC Pharmaceuticals Crescita futura

Criteri Future verificati 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Insufficient new directors

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2026

ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings

ORIC Pharmaceuticals, Inc. Reports Selection Of Rinzimetostat RP3D In Combination With Darolutamide For Himalayas-1 Phase 3 Global Study With Dose Optimization Data Supporting Its Potential Best-In-Disease Profile

Oric Pharmaceuticals Reports Combination Dose Optimization Data From Phase 1b Trial Of Rinzimetostat In Patients With Metastatic Castration Resistant Prostate Cancer

ORIC Pharmaceuticals, Inc. Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

ORIC Pharmaceuticals, Inc. Announces Completion of Dose Exploration Portion of ORIC-944 Phase 1b Clinical Trial and Continues to Demonstrate Potential Best-in-Class Efficacy and Safety

ORIC Pharmaceuticals, Inc. Announces Publication in Cancer Research on the Discovery and Development of Enozertinib

ORIC Pharmaceuticals, Inc. Presents Preclinical Data At the Eortc-Nci-Aacr International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-In-Class Potential of ORIC-944 to Treat Patients with Prostate Cancer and Other Solid Tumors

Oric Pharmaceuticals, Inc. Appoints Kevin Brodbeck as Chief Technical Officer

ORIC Pharmaceuticals, Inc. announced that it has received $124.999983 million in funding from a group of investors

Oric Pharmaceuticals, Inc. Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 11, 2025

ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs

ORIC Pharmaceuticals, Inc. Provides Early Phase 1b Combination Data for ORIC-944

New major risk - Revenue and earnings growth

ORIC Pharmaceuticals, Inc. Appoints Keith Lui as Senior Vice President of Commercial and Medical Affairs

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer

ORIC Pharmaceuticals, Inc., Annual General Meeting, Jun 12, 2024

ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC

ORIC Pharmaceuticals, Inc Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

ORIC Pharmaceuticals, Inc. announced that it has received $125 million in funding from Viking Global Investors LP, Commodore Capital LP, Frazier Management, L.L.C., Frazier Life Sciences Management, LP, VR Adviser, LLC, Nextech Invest Ltd.

ORIC Pharmaceuticals, Inc. Provides Initial Phase 1B Data for Oric-944

ORIC Pharmaceuticals, Inc. Announces Initial Data from the Ongoing ORIC-533 Phase 1 Dose Escalation Trial in Patients with Relapsed/Refractory Multiple Myeloma At the 65th American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations

New major risk - Share price stability

ORIC Pharmaceuticals, Inc. announced that it has received $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals, Inc. announced that it expects to receive $84.7 million in funding from Nextech Invest Ltd., Frazier Life Sciences Management, LP, VR Adviser, LLC, Boxer Capital LLC, EcoR1 Capital, LLC and other investors

ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer

ORIC Pharmaceuticals, Inc. Presents Preclinical Data Demonstrating Oric-533 as A Potential Best-In-Class CD73 Inhibitor at the 64th American Society of Hematology Annual Meeting

ORIC Pharmaceuticals, Inc.(NasdaqGS:ORIC) dropped from Russell 2000 Dynamic Index

President recently bought €1.2m worth of stock

ORIC Pharmaceuticals Announces Regulatory Clearance of Clinical Trial Application for ORIC-114 in Advanced Solid Tumors with EGFR or HER2 Exon 20 Alterations or HER2 Amplifications

ORIC Pharmaceuticals, Inc. Provides Corporate Update and Highlights Key Upcoming Milestones

ORIC Pharmaceuticals, Inc. Presents Data Supporting the Therapeutic Potential of ORIC3 in Multiple Myeloma At the American Society of Hematology (ASH) Annual Meeting

ORIC Pharmaceuticals, Inc. Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

ORIC Pharmaceuticals, Inc. Announces Initial Data from an Ongoing Phase 1B Study Evaluating Oric-10

Independent Director & Member of Scientific Advisory Board Richard Scheller has left the company

ORIC Pharmaceuticals, Inc. Reports Initial Clinical Data Being Presented at ASCO from Phase 1B Trial of ORIC-101 in Combination with Nab-Paclitaxel

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

ORIC Pharmaceuticals, Inc. Provides Corporate Update

ORIC Pharmaceuticals Announces Initiation of Expansion Cohorts in Phase 1b Study of ORIC-101

New 90-day high: €30.20

New 90-day high: €22.80

ORIC Pharmaceuticals, Inc. Enters into an Exclusive License Agreement with Voronoi, Inc

New 90-day low: €17.00

ORIC Pharmaceuticals, Inc. announced that it expects to receive funding from a group of investors

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali

Fonti analitiche